Indication
Anti-Angiogenesis
1 clinical trial
1 product
Clinical trial
A Phase II, Prospective, Randomized, Open Label, Multi-center Study of Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant With Resectable Stage II-IIIB Non-Small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2025-06-10
Product
Immunochemotherapy